Literature DB >> 3920309

B cells in patients with X-linked agammaglobulinemia.

M E Conley.   

Abstract

X-linked agammaglobulinemia (XLA) has been described as a disorder in which pre-B cells fail to differentiate into B cells. However, a small number of B cells have been seen occasionally in patients with this disorder. Because the phenotype of these cells might be helpful in defining the site of the defect in XLA, immunofluorescent staining techniques were used to characterize the B cells that can be found in patients with XLA. Surface IgM-positive B cells could be detected in the peripheral circulation of all seven patients studied. These B cells constituted a very small percentage of the total lymphocytes (0.01 to 0.3% compared with 3.2 to 13.7% in controls) and differed in phenotype from control B cells. They were much more brightly stained for surface IgM (p less than 0.001) and less brightly stained for Ia (p less than 0.01). This phenotype is similar to that described for immature B cells in the mouse. Over 80% of the patients' B cells expressed surface IgD, and all expressed the B cell marker B1, but only 35% expressed the B cell marker B2. This B cell marker, which is the C3d receptor and the Epstein-Barr virus receptor, is expressed later in ontogeny than B1 and can be detected on over 80% of control B cells. All B cells expressed either kappa or lambda light chain. These findings indicate that the defect in differentiation of pre-B cells into B cells is not absolute in patients with XLA. The immature phenotype of the B cells additionally suggests that there may be a block in the maturation of B cells at more than one stage of differentiation in this disorder.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3920309

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

Review 1.  Early B cell defects.

Authors:  H B Gaspar; M E Conley
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

Review 2.  X-linked agammaglobulinemia.

Authors:  M E Conley; J Rohrer; Y Minegishi
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 8.667

3.  Increased pro-inflammatory cytokine production after lipopolysaccharide stimulation in patients with X-linked agammaglobulinemia.

Authors:  María Edith González-Serrano; Iris Estrada-García; Dolores Mogica-Martínez; Alejandro González-Garay; Gabriela López-Herrera; Laura Berrón-Ruiz; Sara Elva Espinosa-Padilla; Marco Antonio Yamazaki-Nakashimada; Alexander Vargas-Hernández; Leopoldo Santos-Argumedo; Sergio Antonio Estrada-Parra; Francisco J Espinosa-Rosales
Journal:  J Clin Immunol       Date:  2012-06-05       Impact factor: 8.317

4.  Evidence for failure of V(D)J recombination in bone marrow pre-B cells from X-linked agammaglobulinemia.

Authors:  J Schwaber
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

Review 5.  Genetics of human X-linked immunodeficiency diseases.

Authors:  R W Hendriks; R K Schuurman
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

Review 6.  The genetic theory of infectious diseases: a brief history and selected illustrations.

Authors:  Jean-Laurent Casanova; Laurent Abel
Journal:  Annu Rev Genomics Hum Genet       Date:  2013-05-29       Impact factor: 8.929

7.  B-cell-specific demethylation of BTK, the defective gene in X-linked agammaglobulinemia.

Authors:  O Parolini; J Rohrer; L H Shapiro; M E Conley
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

8.  XLA patients with BTK splice-site mutations produce low levels of wild-type BTK transcripts.

Authors:  Jeroen G Noordzij; Sandra de Bruin-Versteeg; Nico G Hartwig; Corry M R Weemaes; Egbert J A Gerritsen; Eva Bernatowska; Stefaan van Lierde; Ronald de Groot; Jacques J M van Dongen
Journal:  J Clin Immunol       Date:  2002-09       Impact factor: 8.317

9.  B cells in patients with X-linked and 'common variable' hypogammaglobulinaemia.

Authors:  J T Golay; A D Webster
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

10.  Unimpaired activation of c-Jun NH2-terminal kinase (JNK) 1 upon CD40 stimulation in B cells of patients with X-linked agammaglobulinemia.

Authors:  Cornelia Brunner; Hans Wolfgang Kreth; Hans D Ochs; Volker Schuster
Journal:  J Clin Immunol       Date:  2002-07       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.